A Study of Male Rectal Samples in Preparation for Future Rectal Microbicide Trials
|ClinicalTrials.gov Identifier: NCT00075062|
Recruitment Status : Completed
First Posted : January 1, 2004
Last Update Posted : August 21, 2008
|Condition or disease||Intervention/treatment|
|HIV Infections HIV Seronegativity||Procedure: Flexible Sigmoidoscopy Procedure: Rectal Biopsy|
Rectal microbicides to prevent HIV transmission are currently being developed in the hope that someday they will be widely used to prevent sexually transmitted HIV. This study will examine variables in male rectal tissue; this information may be useful for future rectal microbicide safety and efficacy studies. The study will evaluate the differences in rectal tissue from HIV infected or uninfected males who either engage in anal-receptive sex (men who sleep with men, or MSM) or do not have anal-receptive sex.
The study will last approximately 7 months, with 6 weeks of follow-up. There are four groups in this study. Groups 1 and 2 will enroll HIV uninfected men; Groups 3 and 4 will enroll HIV infected men. Groups 1, 3, and 4 will comprise MSM who engage in anal-receptive sex; Group 2 will comprise men who do not. Patients will provide medical and medication history, undergo a complete physical exam, and receive HIV counseling at screening. An anoscopy (examination of the anus, anal canal, and lower rectum) and blood draw will be conducted at screening, study entry, and Weeks 2 and 4. Rectal secretions will be collected and a sigmoidoscopy (an internal examination of the rectum, distal sigmoid colon, and large bowel using a small camera) will be performed at study entry and Weeks 2 and 4.
|Study Type :||Observational|
|Estimated Enrollment :||16 participants|
|Official Title:||Characteristics of Baseline Mucosal Indices of Injury and Inflammation in Men For Use in Rectal Microbicide Trials|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00075062
|United States, California|
|David Geffen School of Medicine at UCLA|
|Los Angeles, California, United States, 90095|
|Study Chair:||Ian McGowan, MD, PhD||University of California, Los Angeles|
|Study Chair:||Peter Anton, MD||University of California, Los Angeles|